Hongbo Gao

Hongbo Gao

Auto-generated profile, based on publicly available information

Hongbo Gao

Department of Urology, Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2025 in Science Advances
Verified
Journal Article
Open access
HGHongbo Gao
Hongbo Gao
SWStephen Q. R. Wong
Stephen Q. R. Wong
ESEthan Subel
Ethan Subel
YHYung Huang
Yung Huang
YLYu-Cheng Lee
Yu-Cheng Lee
KCKeith Syson Chan
Keith Syson Chan
The impact of chemotherapy-induced tumor cell pyroptosis on fibroblasts, a key stromal cell type within the tumor microenvironment (TME), remains unexplored. Here, we report morphologically and molecularly distinct subtypes of cancer-associated fibroblasts (CAFs) in bladder cancer, including αSMA + IL-6 − myofibroblastic CAFs (myCAFs), αSMA − IL-6 + inflammatory CAFs (iCAFs), and hybrid i/myCAFs. Caspase-1–dependent tumor pyroptosis releases several inflammatory chemokines, converting αSMA + CAF into iCAFs in a CCR6-dependent manner. This is clinically relevant, as a fibroblast gene signature driven by iCAF markers and collagen type III is enriched in patients with chemoresistant bladder cancer after neoadjuvant chemotherapy. Contrary to the current notion, iCAFs, rather than myCAFs, produce collagen III in response to chemotherapy, supporting the expansion of cancer stem cells (CSCs). Thus, tumor cell pyroptosis initiates an iCAF-CSC feedforward loop that drives chemoresistance, indicating that inflammatory cell death is not universally beneficial to anticancer therapy, depending on the target cell type.

18 May 2023 in Asian Journal of Surgery
Verified
Journal Article
Open access
YZYujun Zhou
Yujun Zhou
HGHongbo Gao
Hongbo Gao